TTNP — Titan Pharmaceuticals Balance Sheet
0.000.00%
- $5.52m
- $2.72m
- 25
- 24
- 55
- 26
Annual balance sheet for Titan Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 5.41 | 6.04 | 2.94 | 6.76 | 2.83 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.884 | 0.112 | 0.036 | 1.05 | 0.062 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 7.33 | 7.23 | 3.6 | 8.02 | 2.92 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.759 | 0.717 | 0.407 | 0.068 | 0 |
| Other Long Term Assets | |||||
| Total Assets | 8.09 | 7.99 | 4.06 | 8.09 | 2.92 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.22 | 2.67 | 2.63 | 1.44 | 0.483 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 4.55 | 2.86 | 2.69 | 1.44 | 0.483 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 3.53 | 5.14 | 1.36 | 6.64 | 2.44 |
| Total Liabilities & Shareholders' Equity | 8.09 | 7.99 | 4.06 | 8.09 | 2.92 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |